.
2696 financial statements
* Numbers in millions
Year |
2019 | 2020 | TTM |
---|---|---|---|
Capitalization * |
19 389 | 20 971 | 9 956 |
EV * |
17 697 | 21 690 | 21 690 |
Stock price ¤ |
39 | 39.6 | 18.8 |
Number of shares * |
497 | 530 | 530 |
EPS |
-1,76 | -1,88 | -1,88 |
Revenue * |
91 | 588 | 588 |
Net income * |
-875 | -994 | -994 |
Operating profit * |
-802 | -890 | -890 |
Total liabilities * |
1 899 | 3 240 | 3 240 |
Net debt * |
-1 692 | 719 | 719 |
Total assets * |
5 900 | 6 439 | 6 439 |
Equity * |
4 000 | 3 199 | 3 199 |
Cash and investments * |
2 301 | 1 114 | 1 114 |
Over the past 10 years, the maximum capitalization of Shanghai Henlius Biotech, Inc. is 20 971, the minimum is 19 389. Maximum net income 0, Minimum net income -994. The maximum price of 2696 shares is 39.6, the minimum price is 39.
.
2696 valuation
Year |
2019 | 2020 | TTM |
---|---|---|---|
P/E |
-22,15 | -21,11 | -10,02 |
P/B |
4,85 | 6,56 | 3,11 |
P/S |
213,23 | 35,69 | 16,94 |
E/P |
-5% | -5% | -10% |
P/FCF |
-12,30 | -9,88 | -4,69 |
.
2696 profitability
Year |
2019 | 2020 | TTM |
---|---|---|---|
ROE |
-22% | -31% | |
ROA |
-24% | -28% | |
ROIC |
-16% | -20% |